	US 12,263,173 B2
	PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
Maya Ridinger, San Diego, CA (US); and Mark Erlander, San Diego, CA (US)
Assigned to Cardiff Oncology, Inc., San Diego, CA (US)
Filed by CARDIFF ONCOLOGY, INC., San Diego, CA (US)
Filed on Jun. 21, 2024, as Appl. No. 18/751,014.
Application 18/751,014 is a continuation of application No. PCT/US2023/073865, filed on Sep. 11, 2023.
Claims priority of provisional application 63/405,466, filed on Sep. 11, 2022.
Claims priority of provisional application 63/515,831, filed on Jul. 26, 2023.
Prior Publication US 2025/0032495 A1, Jan. 30, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 35/04 (2006.01); A61K 45/06 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 35/04 (2013.01); A61K 45/06 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)]

20 Claims

1. A method of selecting a subject with a metastatic colorectal cancer for a treatment with onvansertib and bevacizumab, the method comprising:

determining a subject suffering from metastatic colorectal cancer has or has not received any prior treatment with bevacizumab;

if the subject has not received any prior treatment with bevacizumab, selecting the subject for a treatment with onvansertib and bevacizumab, wherein the treatment after administration of onvansertib and bevacizumab to the subject reduces or inhibits progression of the metastatic colorectal cancer in the subject; and

if the subject has received any prior treatment with bevacizumab, not selecting the subject for the treatment with onvansertib and bevacizumab.